Repligen Corp (RGEN) financials

Repligen Corp (RGEN) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Repligen Corp reported revenue of $738M, up 16.4% year over year, net income of $49M, diluted EPS of $0.86 and free cash flow of $92M.

Revenue (fiscal 2025)

$738M

Revenue growth (fiscal 2025)

16.4%

Net income (fiscal 2025)

$49M

Diluted EPS (fiscal 2025)

$0.86

Free cash flow (fiscal 2025)

$92M

Repligen Corp files with the U.S. Securities and Exchange Commission under CIK 0000730272, classified as Biological Products, (No Diagnostic Substances).

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.